Show results for
Refine by
Detects Cancer Early Articles & Analysis
52 news found
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
“We are focused on building out our portfolio of assays for early cancer detection and treatment management while maintaining our commitment to continual improvement of our products,” stated Rashid Bux, CEO of BioMark. ...
Julia Camps Herrero, Corporate Chief of Breast Health, Ribera Salud Hospitals Spain. “Early detection of cancer can save lives. Imaging options such as contrast-enhanced mammography can help improve diagnostic accuracy, potentially identifying cancers that otherwise might have been ...
ByBayer AG
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer ...
Its pipeline of products includes two mono-cancer tests designed for early detection of Prostate Cancer and Acute Myeloid Leukemia, and an early detection multi-cancer test to identify any of multiple cancers in a subject from a simple blood draw. “Our ...
(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating ...
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early ...
” INOVIQ has multiple patents and patent applications covering its exosome capture and biomarker technologies and products, and was recently granted new patents in the US and Australia for its SubB2M technology. Detecting early-stage cancers Cancers are often diagnosed at late-stage after symptoms have appeared, ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
The study concluded that "Artificial intelligence (AI)–based screening could detect normal, moderate-risk, and suspicious mammograms in a breast cancer screening programme, which may reduce the radiologist workload. ...
(Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC). The test, which only requires patients to complete a simple blood draw, is intended for adults age 45 and older who are not up to date with ...
He has been instrumental in launching and scaling many industry-first technologies including the first Computer Aided Detection algorithm for the early detection of breast cancer, the first mammography analytics platform and a multi-point risk stratified breast screening scorecard. ...
” “GRAIL is deeply committed to detecting cancer early when treatments are more effective and there is potential for cure. Recent research has estimated the impact of multi-cancer early detection (MCED) testing on the ability to find more cancer types, in earlier ...
That’s why it’s so important to find lung cancer early, before symptoms start,” said Craig Eagle, MD, Guardant Health chief medical officer. “Unfortunately, many people do not follow recommended screening guidelines for lung cancer. We believe a simple blood test could help improve screening rates and ...
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, ...
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test. ...
Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix. Read the full new here ...
ByAmadix
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence. ...
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan ...